Find uplifting stories about heroes, innovations, and solutions
6696 results for "obesity-treatment"
The American Medical Association just adopted sweeping policies to make weight loss medications and comprehensive obesity care more affordable for millions of Americans. The move addresses one of healthcare's biggest cost barriers while recognizing obesity as a chronic disease requiring long-term support.
A breakthrough obesity treatment helped patients lose nearly 30% of their body weight—results previously only achievable through surgery. The experimental drug could transform how millions manage obesity while Medicare makes these treatments more affordable.
France just became the first EU country to cover breakthrough obesity medications for severely obese patients, helping one million people access treatments that previously cost €300 per month. The bold public health move recognizes obesity as a serious medical condition deserving national support.
Eli Lilly has granted one person extraordinary access to its next-generation obesity treatment through an FDA compassionate use program. The decision marks a rare exception that could offer hope to patients waiting for breakthrough treatments.
Doctors are discovering why weight-loss drugs work brilliantly for some people but fail for others. The answer could revolutionize how we treat obesity within just a few years.
A new class of medications is transforming obesity treatment by working with the body's hunger signals rather than against them, helping patients lose up to 30% of their body weight. These GLP-1 drugs are proving that obesity has deep biological roots beyond willpower alone.
Millions of Americans struggling with obesity now have a new option: the FDA just approved Foundayo, the first oral tablet in a groundbreaking class of weight-loss medications. This pill could transform treatment by offering an easier alternative to weekly injections.
A new obesity treatment that only requires monthly injections continues to show promising results, offering hope for easier weight loss options. Patients in a recent study lost over 12% of their body weight without hitting a plateau.
%2Ffile%2Fattachments%2F2992%2F13971407_975900.jpg)
Starting mid-June, France becomes the first EU nation to reimburse life-changing weight-loss medications for severely obese patients. Up to one million people could access treatments that currently cost €300 monthly out of pocket.
Doctors at Mayo Clinic are successfully pairing weight loss surgery with medications like Ozempic to help patients overcome obesity. This combined approach offers new hope for people who need more support than one treatment alone can provide.
A new experimental obesity treatment targeting three hormones has shown significant weight loss in early testing. The "triple-G" drug from Kailera offers fresh hope in the rapidly expanding field of weight management medicine.
Researchers created a groundbreaking tool that predicts obesity complications more accurately than BMI alone, considering family history, diet, and lifestyle factors. The advancement could help millions get the right treatment at the right time.
A new obesity treatment from pharmaceutical company Boehringer has shown promising results, helping patients lose an average of 16.6% of their body weight in clinical trials. The breakthrough adds another tool to the growing arsenal of effective weight loss medications changing lives worldwide.
A new, stronger version of the popular weight loss medication Wegovy just got FDA approval, giving more Americans access to potentially more effective obesity treatment. The approval came through a new fast-track program designed to speed up medicines that address major health priorities.
Eli Lilly is building a $3.5 billion manufacturing facility in Pennsylvania to produce breakthrough obesity treatments, including an experimental drug showing record-breaking weight loss results. The plant will create 850 permanent jobs and 2,000 construction positions when it opens in 2031.
More than 10 million Americans just regained insurance coverage for a life-changing obesity treatment after CVS reversed its restrictions on Zepbound. The win came after drugmaker Eli Lilly slashed prices to make the medication more accessible.
A groundbreaking trial found that semaglutide, the popular weight loss drug, significantly reduced alcohol cravings and heavy drinking days in people battling both obesity and alcohol addiction. The discovery could transform treatment options for millions worldwide struggling with alcohol use disorder.
Canadians living with obesity and sleep apnea now have a new treatment option that tackles both conditions at once. Health Canada just approved Zepbound, a medication that helps patients lose weight while reducing dangerous breathing interruptions during sleep.
A pill-based weight loss medication achieved up to 12% body weight reduction in clinical trials, offering a more accessible alternative to injectable drugs like Ozempic. The oral drug could transform obesity treatment by eliminating needles, refrigeration, and high manufacturing costs.
After 21 years of groundbreaking nutrition research at the NIH, Dr. Kevin Hall retired early but didn't stop fighting to help people understand food and health. He's now designing obesity treatments at a pharmaceutical company and sharing his discoveries in a new book.
Showing 20 of 6696